Erik Nerpin’s current holding totals 20,533 series B shares. Nerpin intends to invest SEK 100,000 in the rights issue as follows: in addition to subscribing for units for his holding of 20,533 unit rights, corresponding to 13,688 units of new series B shares, he will also subscribe for a further 14,884 units with new series B shares without the support of preferential rights. In parallel, Diamyd Medical wishes to announce that Board member Maria-Teresa Essen-Möller and CFO Anna Styrud intend to subscribe for their full shares, corresponding to SEK 74,667 and SEK 93,333, respectively. As previously announced, CEO Ulf Hannelius intends to subscribe for his full share in the rights issue, which corresponds to SEK 116,667. The total amount for the units to which key executives intend to subscribe is SEK 384,667.

Regarding Diamyd Medical’s press release dated May 8, the Company wishes to clarify that of the 46,667 series B shares and 953,333 unit rights encompassed by the transaction, PGVinvest AB acquired the unit rights. The series B shares were sold in the market. As announced, Anders Essen-Möller will use the entire proceeds raised as part of his investment in the rights issue.

The subscription period for Diamyd Medical’s rights issue will commence today, Wednesday, May 10 and extend until Wednesday, May 24.

For further information on the right issue, please see www.diamyd.com.

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd^®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Five clinical studies are ongoing with Diamyd^®. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.

This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. This is an English translation of information that was submitted for publication, through the agency of the contact person set out above, at 8:30 CET on May 10, 2017.